Expertise in
7
conditions

Dr. Miriam A. Bornhorst

Hematology | Oncology
Ann & Robert H. Lurie Children's Hospital Of Chicago
225 E Chicago Ave, 
Chicago, IL 
18 Years of Experience
Expertise in
7
conditions
Ann & Robert H. Lurie Children's Hospital Of Chicago
225 E Chicago Ave, 
Chicago, IL 

Overview

Miriam Bornhorst is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. She has been practicing medicine for over 18 years.

Dr. Bornhorst is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Neurofibromatosis, Neurofibromatosis Type 1 (NF1), Brain Tumor, and Glioma.

She is actively involved in clinical research, co-authoring 49 peer reviewed articles and participating in 3 clinical trials.

Graduate Year

2008

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in DC

Languages Spoken

English
Polish
Spanish

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

Ann & Robert H. Lurie Children's Hospital of Chicago
225 E Chicago Ave, Chicago, IL 60611

Additional Areas of Focus

Dr. Bornhorst has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drug: Mirdametinib
Study Phase: Phase 2
Frameshift Peptides of Children With Neurofibromatosis Type 1 (NF1) and Either Low-Grade Gliomas or Plexiform Neurofibromas
Frameshift Peptides of Children With Neurofibromatosis Type 1 (NF1) and Either Low-Grade Gliomas or Plexiform Neurofibromas
Enrollment Status: Completed
Publish Date: August 31, 2022
Intervention Type: Genetic
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1 With Inoperable, Progressive/Symptomatic Plexiform Neurofibromas (PN)
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1 With Inoperable, Progressive/Symptomatic Plexiform Neurofibromas (PN)
Enrollment Status: Approved_for_marketing
Publish Date: May 01, 2020
Intervention Type: Drug
View 2 Less Clinical Trials

49 Total Publications

Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series.
Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series.
Journal: Neuro-oncology advances
Published: April 27, 2026
Similar Doctors
Expertise in
25
conditions
Dr. Sonali M. Smith
Hematology | Oncology
Expertise in
25
conditions
Dr. Sonali M. Smith
Hematology | Oncology
Referral may be required

UChicago Medicine River East

355 E. Grand Ave., 
Chicago, IL 
 (0.4 miles away)
888-824-0200
Languages Spoken:
English, Greek, Gujarati , Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sonali Smith is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Smith is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Smith is board certified in Medical Oncology and Practicing Since2001. Dr. Smith is currently accepting new patients.

Expertise in
17
conditions
Dr. Jessica K. Altman
Hematology | Oncology
Expertise in
17
conditions
Dr. Jessica K. Altman
Hematology | Oncology
Referral may be required
Before you request
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.4 miles away)
866-587-4322
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jessica Altman is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Altman is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Altman is board certified in American Board Of Internal Medicine - Hematology (Certified). Dr. Altman is currently accepting new patients.

Expertise in
22
conditions
Dr. Sherif M. Badawy
Hematology | Oncology
Expertise in
22
conditions
Dr. Sherif M. Badawy
Hematology | Oncology
Referral may be required

Ann & Robert H. Lurie Children's Hospital Of Chicago

225 E Chicago Ave, 
Chicago, IL 
 (0.1 miles away)
312-227-4813
Languages Spoken:
English
See accepted insurances

Sherif Badawy is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Badawy is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Bone Marrow Transplant, and Bone Graft.

Frequently Asked Questions about Dr. Miriam A. Bornhorst

How do I make an appointment with Dr. Miriam A. Bornhorst?

You can book an appointment with Dr. Miriam A. Bornhorst by calling their office at 312-227-4090. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Miriam A. Bornhorst a top-rated expert for Neurofibromatosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Miriam A. Bornhorst is classified as an Elite expert for Neurofibromatosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Miriam A. Bornhorst specialize in?

While Dr. Miriam A. Bornhorst is a Hematology, they have specific expertise in Neurofibromatosis, Neurofibromatosis Type 1 (NF1), and Brain Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Miriam A. Bornhorst participate in research or clinical trials?

Yes. Dr. Miriam A. Bornhorst has published 49 articles and abstracts on conditions like Neurofibromatosis. You can view a list of Dr. Miriam A. Bornhorst's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Miriam A. Bornhorst accept my insurance?

Dr. Miriam A. Bornhorst accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 312-227-4090 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bornhorst's expertise for a condition
ConditionClose
View All 48 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile